Management of West syndrome during COVID-19 pandemic: A viewpoint from South Asian West Syndrome Research Group

Epilepsy Res. 2020 Nov:167:106453. doi: 10.1016/j.eplepsyres.2020.106453. Epub 2020 Aug 31.

Abstract

In the wake of the pandemic COVID-19 and nationwide lockdowns gripping many countries globally, the national healthcare systems are either overwhelmed or preparing to combat this pandemic. Despite all the containment measures in place, experts opine that this novel coronavirus is here to stay as a pandemic or an endemic. Hence, it is apt to be prepared for the confrontation and its aftermath. From protecting the vulnerable individuals to providing quality care for all health conditions and maintaining essential drug supplies, it is going to be a grueling voyage. Preparedness to sustain optimal care for each health condition is a must. With a higher risk for severe COVID-19 disease in infants, need of high-dose hormonal therapy with a concern of consequent severe disease, presence of comorbidities, and a need for frequent investigations and follow-up; children with West syndrome constitute a distinctive group with special concerns. In this viewpoint, we discuss the important issues and concerns related to the management of West syndrome during COVID-19 pandemic in the South Asian context and provide potential solutions to these concerns based on the current evidence, adeptness, and consensus. Some plausible solutions include the continuation of containment and mitigation measures for COVID-19, therapeutic decision- making for West syndrome based on risk stratification, and tele-epileptology.

Keywords: COVID-19; Epileptic spasms; Infantile spasms; Infants.

MeSH terms

  • Adrenal Cortex Hormones / supply & distribution
  • Adrenal Cortex Hormones / therapeutic use*
  • Adrenocorticotropic Hormone / supply & distribution
  • Adrenocorticotropic Hormone / therapeutic use*
  • Anticonvulsants / supply & distribution
  • Anticonvulsants / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Betacoronavirus
  • COVID-19
  • Clinical Decision-Making
  • Coronavirus Infections / drug therapy*
  • Delivery of Health Care
  • Drug Interactions
  • Humans
  • Infant
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • SARS-CoV-2
  • Spasms, Infantile / drug therapy*
  • Telemedicine*
  • Time-to-Treatment
  • Vigabatrin / supply & distribution
  • Vigabatrin / therapeutic use*

Substances

  • Adrenal Cortex Hormones
  • Anticonvulsants
  • Antiviral Agents
  • Adrenocorticotropic Hormone
  • Vigabatrin